Clinical trials: Neuroendocrine Cancer
Metastatic Melanoma, Skin Cancer
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
Background: Tumor infiltrating lymphocytes (TIL) are white blood cells that have been taken from tumor tissue. The cells are modified to help them kill tumor cells, then given back to the person with cancer.
- Trial name
- NCT01369875
- Testing
- Cyclophosphamide, Fludarabine, Aldesleukin
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Uveal Melanoma
Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy
The study is designed to determine the 32 month rate of distant relapse in patients with uveal melanoma who are at high risk of recurrence following definitive therapy with surgery or radiation who receive adjuvant crizotinib…
- Trial name
- NCT02223819
- Testing
- Crizotinib
- Where
- 4 sites in United States
- Volunteers
- 34 people
- Sponsor
- Columbia University
Melanoma
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma
The purpose of this study is to determine the effectiveness of nivolumab adjuvant immunotherapy compared to placebo in adults and pediatric participants after complete resection of Stage IIB/C melanoma with no evidence of disease…
- Trial name
- CheckMate76K (NCT04099251)
- Testing
- Nivolumab
- Where
- 130 sites in United States, Australia and 18 more
- Volunteers
- 790 people
- Sponsor
- Bristol-Myers Squibb
Metastatic/Locally Advanced, Non-resectable, Duodeno-pancreatic Neuroendocrine Tumours
A Study Evaluating Lanreotide as Maintenance Therapy in Patients With Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors (REMINET)
This European, prospective, multicentre, double-blind randomised study will evaluate the effect of lanreotide (120 mg every 28 days until disease progression) versus placebo in patients with metastatic/locally advanced…
- Trial name
- REMINET (NCT02288377)
- Testing
- lanreotide
- Where
- 24 sites in Belgium, France and 2 more
- Volunteers
- 53 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Medullary Thyroid Cancer
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that…
- Trial name
- LIBRETTO-531 (NCT04211337)
- Testing
- Selpercatinib, Cabozantinib, Vandetanib
- Where
- 143 sites in United States, Australia and 18 more
- Volunteers
- 291 people
- Sponsor
- Loxo Oncology, Inc.
Locally Advanced Unresectable or Metastatic Melanoma
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Approximately 40 participants with locally advanced or metastatic melanoma will be enrolled in 20 sites in the United States into 1 of the following 2 arms: Primary resistance to initial checkpoint inhibitor (CPI) therapy in Arm…
- Trial name
- NCT04768881
- Testing
- Selinexor, Pembrolizumab
- Where
- 13 sites in United States
- Volunteers
- 15 people
- Sponsor
- Karyopharm Therapeutics Inc
Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
This phase Ib trial studies how well pembrolizumab works with combination chemotherapy in treating participants with small cell/neuroendocrine cancers of the urothelium or prostate that has spread to nearby tissue or lymph nodes…
- Conditions
- Bladder Small Cell Neuroendocrine Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma
- Trial name
- NCT03582475
- Testing
- Carboplatin, Cisplatin, Docetaxel
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Melanoma
Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Current therapeutic approaches available for patients with advanced-stage melanoma remain inadequate, and existing approaches including those involving immunotherapy with cytokines and/or targeted strategies have resulted in…
- Trial name
- NCT01876212
- Testing
- DC vaccine, Dasatinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Walter J. Storkus
Melanoma
Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)
This study will assess the safety, tolerability, and efficacy of every-3-week dosing (Q3W) of pembrolizumab (MK-3475) in participants with advanced melanoma; participants may receive pembrolizumab for up to 2 years if deriving…
- Trial name
- NCT02180061
- Testing
- Pembrolizumab
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma (Skin), Cutaneous Melanoma
A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
The purpose of this study is to evaluate the efficacy and safety of ANV419 monotherapy or the combination of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or…
- Conditions
- Melanoma (Skin), Cutaneous Melanoma, Adult Disease, Advanced Solid Tumor
- Trial name
- NCT05578872
- Testing
- ANV419
- Where
- 25 sites in United States, France and 3 more
- Volunteers
- 29 people
- Sponsor
- Anaveon AG
Melanoma
Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma
The purpose of this study is to see how much of the drug Yervoy can be safely tolerated when it is given to people who are also receiving a drug called Sylatron.
- Trial name
- NCT01496807
- Testing
- Sylatron, Yervoy
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma, Lung Cancer
Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic Melanoma or NSCLC
This is a 2-part prospective trial examining the ability of Stereotactic Body Radiation Therapy (SBRT) to induce a response to MK-3475, a humanized antibody to PD-1, in patients who progress on this antibody.
- Trial name
- NCT02407171
- Testing
- MK-3475, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- Yale University
BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC
Phase 1 Safety Study of Encorafenib in Chinese Patients With Advanced Metastatic BRAF V600E Mutant Solid Tumors
This is a phase 1, multicenter, open-label, single-arm study to investigate the safety and tolerability of encorafenib 300 mg once daily (QD) monotherapy in adult Chinese participants with B-RAF Proto-oncogene, Serine/threonine…
- Conditions
- BRAF V600E Unresectable or Metastatic Melanoma, BRAF V600E Metastatic NSCLC, Melanoma
- Trial name
- OCEANI (NCT05003622)
- Testing
- Encorafenib
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Pierre Fabre Medicament
Neuroendocrine Tumors
A Study of Pembrolizumab in Patients With Neuroendocrine Tumors
The purpose of this research study is to test if pembrolizumab is safe and effective for treating patients with metastatic high-grade neuroendocrine tumors who have failed platinum based chemotherapy.The study drug, pembrolizumab…
- Trial name
- NCT02939651
- Testing
- Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Fox Chase Cancer Center
Metastatic Cancer, Metastatic Renal Cancer
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
Background: MAGE-A3/12 is a type of protein commonly found on certain types of cancer cells, particularly in metastatic cancer. Researchers have developed a process to take lymphocytes (white blood cells) from cancer patients…
- Conditions
- Metastatic Cancer, Metastatic Renal Cancer, Metastatic Melanoma
- Trial name
- NCT01273181
- Testing
- PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes, Aldesleukin, Cyclophosphamide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Cancer Institute (NCI)
Gastrinoma, Glucagonoma
Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
This phase II trial is studying how well sorafenib tosylate works in treating patients with progressive metastatic neuroendocrine tumors.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00131911
- Testing
- sorafenib tosylate
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Melanoma, Stage IA Skin Melanoma
Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery
This pilot clinical trial studies intravital microscopy for identifying tumor vessels in patients with stage IA-IV melanoma that is being removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IA Skin Melanoma, Stage IB Skin Melanoma, Stage IIA Skin Melanoma
- Trial name
- NCT01886235
- Testing
- Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic Melanoma, Skin Cancer
Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...
Background: An experimental treatment for metastatic melanoma involves cell therapy, in which researchers take white blood cells (lymphocytes) from the tumor tissue, grow them in the laboratory in large numbers, and then use the…
- Trial name
- NCT01319565
- Testing
- Aldesleukin, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)
The purpose of this study is to determine the safety, tolerability, and objective response rate (ORR) of pembrolizumab (MK-3475) in Chinese participants with locally advanced or metastatic melanoma, with disease progression…
- Trial name
- NCT02821000
- Testing
- Pembrolizumab
- Volunteers
- 103 people
- Sponsor
- Merck Sharp & Dohme LLC
Cancer, Melanoma
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
The purpose of this study is to investigate experimental medication BMS-986253 in combination with Nivolumab or Nivolumab plus Ipilimumab in participants with advanced cancers.
- Trial name
- NCT03400332
- Testing
- BMS-986253, Nivolumab, Ipilimumab
- Where
- 72 sites in United States, Australia and 10 more
- Volunteers
- 281 people
- Sponsor
- Bristol-Myers Squibb